Compare Abeona Therapeutics Inc (ABEO) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Vanguard High Dividend Yield ETF — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Vanguard High Dividend Yield ETF trades at $159.81. The key difference: Vanguard High Dividend Yield ETF is trading nearer its 52-week high, Abeona Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | VYM | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $161.17 |
52-Week Low | $4.17 | $132.90 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
VYM trades at $160.14, up 0.41% with a bullish technical outlook supported by moving averages. The ETF focuses on high dividend yield stocks, offering investors steady income through quarterly distributions. Recent news highlights strong investor interest in dividend ETFs for retirement income, with VYM being frequently compared to peers like VIG and SCHD for its diversification and low 0.04% expense ratio.
VYM presents a compelling income-focused investment with stable technical momentum, though RSI levels suggest potential near-term consolidation. The fund's broad diversification across 618 stocks provides resilience, but investors should monitor sector concentration risks and interest rate sensitivity that could impact dividend sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
